Boston Scientific is once again dropping its outlook for 2026 amid challenges among key revenue drivers. The Marlborough firm started off 2026 by saying its net sales growth would be 10% to 11% on an organic basis. That range dropped to 6.5% and 8% a few months ago, and was reduced to 5% to 6% on Wednesday. Stream NBC10 Boston news for free, 24/7, wherever you are. WATCH HERE WATCH HEREMore on this story from Boston Business Journal